Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CHYM vs CWAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHYM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

CHYM Overall Winner 6-Pillar Tally: CHYM 4 – 2 CWAN Matrix Metrics: CHYM 6 – 4 CWAN

As of Nov 20, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Clearwater Analytics Holdings, Inc. (CWAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHYM carries a Unified Composite Score of 41.9/100 (SELL) at $30.34 (15.3x Forward P/E, 19.3% operating margin), whereas CWAN carries 63.2/100 (BUY) at $24.56 (94.5x Forward P/E, 4.1% operating margin).

  • Composite vs. Pillar Nuance: While CWAN currently prints a higher short-term Unified Composite Score (63.2/100 BUY vs. CHYM 41.9/100 SELL), CHYM captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. 4.1% operating margin) and revenue trajectory (+32.1% vs. +74.4% YoY).
  • Technical & Structure Timing Caution: CHYM is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile CWAN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHYM vs CWAN
CHYM NASDAQ Head-to-Head Winner
Chime Financial, Inc. Class A Common Stock
Finance Services
$30.34
-1.65% 1D
Market Cap $11.8B
TTM Revenue $14.3B
Forward P/E 15.3x
Beta / 30D Vol 1.42β · 43% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 37.0 Fund 48.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 46
RSI-14: 46.4 · SMA20: $30.81 · SMA50: $29.82
CWAN NYSE
Clearwater Analytics Holdings, Inc.
Services-Prepackaged Software
$24.56
+0.04% 1D
Market Cap $7.3B
TTM Revenue $826M
Forward P/E 94.5x
Beta / 30D Vol 0.42β · 4% Vol
Unified Composite Score
63.2 / 100 BUY
Tech 75.0 Fund 62.0 Flow 69.0 Mom 29.5
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.3% over 20 days), RSI 68
RSI-14: 67.9 · SMA20: $24.38 · SMA50: $24.29

6-Pillar Scorecard Institutional Category Breakdown (CHYM 4 – 2 CWAN)

Columns: Metric · CHYM · CWAN
1. Valuation Multiples CHYM
Forward P/E 15.3x 94.5x
Trailing P/E 27.1x 35.6x
PEG Ratio N/M 1.78x
EV / Revenue 0.6x 8.9x
2. Growth & Scale CWAN
Revenue Growth (YoY) +32.1% +74.4%
Earnings Growth (YoY) -33.8% +202.8%
TTM Revenue (USD) $14.3B $826M
Market Cap $11.8B $7.3B
3. Profitability & Quality CHYM
Gross Margin 89.4% 66.0%
Operating Margin 19.3% 4.1%
Net Profit Margin 3.0% -5.8%
Return on Equity (ROE) 5.4% -3.1%
4. Balance Sheet & Cash Flow CHYM
Cash Generation (TTM) $2.27B $109M EBITDA
Cash Flow Margin 15.8% 13.2% EBITDA Mgn
Net Cash / Leverage $2.77B Net Cash $6.89 Book/Sh · -3.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CWAN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 83.7% (100th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 0.19x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat CHYM
OpEx & R&D Intensity 70.1% of Rev ($10.1B) 61.9% of Rev ($511M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHYM (6) vs CWAN (4)
Institutional Metric CHYM CWAN Criterion Row Edge
Market Capitalization
Scale
$11.8B $7.3B Larger Scale CHYM
Trailing P/E Ratio
Valuation
27.1x 35.6x Lower Multiple CHYM
Forward P/E Ratio
Valuation
15.3x 94.5x Lower Multiple CHYM
Revenue Growth (YoY)
Growth
+32.1% +74.4% Higher Growth CWAN
Operating Margin (TTM)
Profitability
19.3% 4.1% Higher Margin CHYM
Net Profit Margin
Profitability
3.0% -5.8% Higher Margin CHYM
Return on Equity (ROE)
Capital Efficiency
5.4% -3.1% Higher ROE CHYM
52-Week Range Position
Momentum
74% ($16–$36) 100% ($16–$25) Stronger Trend CWAN
Beta / 30D Volatility
Risk Regime
1.42β · 43% Vol 0.42β · 4% Vol Lower Realized Risk CWAN
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 63.2 / 100 (BUY) Higher Composite CWAN
Trailing 12M Revenue (USD)
Operating Scale
$14.3B $826M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.4% 66.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev 1.78x PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.27B ($2.77B Net Cash) $109M EBITDA ($6.89 Book/Sh · -3.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CWAN +3.35 pp
CHYM: -2.36% · CWAN: +0.99%
3M Horizon CWAN +12.12 pp
CHYM: -6.21% · CWAN: +5.91%
6M Horizon CWAN +42.26 pp
CHYM: -32.64% · CWAN: +9.62%
1Y Horizon CWAN +24.4 pp
CHYM: -5.7% · CWAN: +18.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHYM vs CWAN. Trailing 12-month operating profitability (CHYM 19.3% vs CWAN 4.1%) and valuation multiples (CHYM 15.3x vs CWAN 94.5x Forward P/E) are benchmarked directly in Pillar 4 below.

CHYM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.3B
Gross Margin89.4%
Op. Margin19.3%
ROE / Fwd P/E5.4% · 15.3x
CWAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$826M
Gross Margin66.0%
Op. Margin4.1%
ROE / Fwd P/E-3.1% · 94.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHYM CONSOLIDATION
52d in phase · OBV DISTRIBUTION
Current IV 83.7%
IV Percentile 100th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CHYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CWAN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact CWAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $34.29 · IV 48.7%

CHYM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,429)

Compare $3,429 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $35 / $37.5 Bull Call Spread

Buy 1x $35C · Sell 1x $37.5C · 32d

Net Entry $91 Debit
T+5d @ +5% Move +$32 (+35%)
Max Risk / Buffer $91 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Jan 15 '27 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 60d

Net Entry $90 Credit
Max Credit / Yield +$90 (+22.0% RoM)
Max Risk / Buffer -13.8% Cushion ($410 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $35 / $32.5 Bear Put Spread

Buy 1x $35P · Sell 1x $32.5P · 32d

Net Entry $125 Debit
T+5d @ -5% Drop +$34 (+27%)
Max Risk / Buffer $125 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHYM Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $11.8B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 70.1% of Rev ($10.1B)
90D Engineering Disclosures 0 Published
CWAN Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $7.3B market capitalization and 4.1% operating margin.
OpEx & R&D Reinvestment 61.9% of Rev ($511M)
90D Engineering Disclosures 0 Published

Investor FAQ CHYM vs CWAN Key Questions & Quantitative Answers

As of Nov 20, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Clearwater Analytics Holdings, Inc. (CWAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHYM carries a Unified Composite Score of 41.9/100 (SELL) at $30.34 (15.3x Forward P/E, 19.3% operating margin), whereas CWAN carries 63.2/100 (BUY) at $24.56 (94.5x Forward P/E, 4.1% operating margin). Composite vs. Pillar Nuance: While CWAN currently prints a higher short-term Unified Composite Score (63.2/100 BUY vs. CHYM 41.9/100 SELL), CHYM captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. 4.1% operating margin) and revenue trajectory (+32.1% vs. +74.4% YoY). Technical & Structure Timing Caution: CHYM is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile CWAN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CWAN leads the Growth & Scale pillar: CHYM posts +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin), compared with CWAN at +74.4% YoY revenue growth and +202.8% YoY earnings growth on $826M TTM revenue (66.0% gross margin, 4.1% operating margin). On trailing 12-month operating scale, CHYM generates $14.3B in USD-normalized revenue versus $826M for CWAN. In operating R&D and SG&A reinvestment, CHYM deploys 70.1% of Rev ($10.1B) (0 90-day corporate R&D disclosures) versus 61.9% of Rev ($511M) (0 disclosures) for CWAN.

CHYM screens cheaper on headline valuation multiples. CHYM trades at 15.3x Forward P/E, 27.1x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (15.8% FCF margin), whereas CWAN trades at 94.5x Forward P/E, 35.6x Trailing P/E, 1.78x PEG, and 8.9x EV/Revenue (13.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHYM (5.4% ROE) versus CWAN (-3.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CHYM carries 83.7% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.42β · 43% Vol realized risk). By comparison, CWAN carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.